secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001628280-23-004701
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M
----------------------------------------------------------------------------

- Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.
- Q4 net income $5.9M ($0.12 diluted) vs $4.5M ($0.09) a year ago; adjusted EBITDA $14.9M (28% margin).
- Full-year 2022 total revenue $164.4M; net loss $16.7M ($0.35 diluted); adjusted EBITDA $24.2M (15% margin).
- 2023 guidance: total revenue $180-188M, MACI $152-156M, burn care $28-32M, gross margin high-60%.
- FDA approved NexoBrid for eschar removal; U.S. commercial launch expected Q2 2023; arthroscopic MACI on track for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/0001628280-23-004701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828023004701/vcel-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-004701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer